Tat-Beclin-1: Dosing Protocols
Dosing guidelines, reconstitution, and administration information
๐TL;DR
- โข3 dosing protocols documented
- โขReconstitution instructions included
- โขStorage: Store lyophilized peptide at -20 degrees C, protected from light and moisture. Reconstituted solutions should be aliquoted into single-use volumes and stored at -20 degrees C or -80 degrees C. Avoid repeated freeze-thaw cycles. Working solutions should be prepared fresh for each experiment when possible.
Protocol Quick-Reference
Autophagy induction research tool
Dosing
Amount
0.5-50 micromolar (in vitro) or 15 mg/kg (mouse IP)
Frequency
Single or daily (varies by experiment)
Duration
Hours to 20 days (varies by model)
Administration
Route
IVSchedule
Daily intraperitoneal injection (in vivo mouse studies)
Timing
In vitro concentrations range from 0.5-50 micromolar. In vivo mouse studies used daily IP injection. No human dosing data exists.
Cycle
Duration
Varies by experimental design
Repeatable
Yes
โ๏ธ Suggested Bloodwork (2 tests)
Autophagy markers (LC3-II/I ratio)
When: Per experimental protocol
Why: Confirm autophagy induction in research models
Cell viability assays
When: Per experimental protocol
Why: Monitor for autosis (autophagy-dependent cell death) at high doses
๐ก Key Considerations
- โPreclinical research tool only; no human clinical trials have been conducted or registered
- โHigh doses trigger autosis (autophagy-dependent cell death); careful dose-response optimization is critical
- โThe retro-inverso D-form is preferred for in vivo use due to enhanced proteolytic stability
Unlock dosing protocols
Free access to research-backed dosing information for all peptides.
150+ peptide profiles ยท 30+ comparisons ยท 18 research tools
| Purpose | Dose | Frequency | Duration | Notes |
|---|---|---|---|---|
| In Vitro Autophagy Induction | Typical in vitro concentrations range from 0.5 to 50 micromolar depending on the cell type and experimental endpoint. Antiviral studies in macrophages used 0.5 to 5 micromolar for HIV-1 inhibition with dose-dependent effects. Higher concentrations (above 20-50 micromolar) may trigger autosis (autophagy-dependent cell death). | Single treatment or repeated dosing during cell culture experiments | Varies by experimental design (hours to days) | The L-form (Tat-L11) is commonly used for in vitro experiments. Tat-Scrambled serves as the standard negative control peptide. Dose-response experiments are critical to identify the therapeutic window between autophagy induction and autosis. |
| In Vivo Antiviral Studies (Mouse, IP) | In the original Shoji-Kawata et al. (Nature 2013) study, mice received 15 mg/kg Tat-Beclin-1 via intraperitoneal injection daily beginning 1 day post-infection with West Nile virus, continuing for 20 days. This dose induced autophagy in peripheral tissues and CNS of neonatal mice. | Daily intraperitoneal injection | 20 days in the West Nile virus survival study | The retro-inverso D-form is preferred for in vivo use due to enhanced resistance to proteolytic degradation. Mouse doses are not translatable to human dosing. No human PK data exists. |
| In Vivo Anticancer Studies (Mouse, IP) | In HER2-positive breast cancer xenograft studies (Vega-Rubin-de-Celis et al., PNAS 2018), Tat-Beclin-1 was administered daily via intraperitoneal injection when tumor volume reached 200 mm3. The peptide was as effective as the clinically approved drug lapatinib in reducing tumor progression. | Daily intraperitoneal injection | Duration of xenograft study until tumor endpoint | Published in PNAS (2018). Mouse xenograft dosing does not predict human anticancer dosing. Specific mg/kg dose for anticancer studies should be confirmed from the primary publication. |
Unlock full dosage protocols
Free access to complete dosing tables and protocol details.
150+ peptide profiles ยท 30+ comparisons ยท 18 research tools
๐Reconstitution Instructions
Tat-Beclin-1 is supplied as lyophilized powder. Reconstitute in sterile water, PBS, or DMSO depending on supplier recommendations and experimental requirements. Typical stock concentration is 1-10 mM. Aliquot reconstituted peptide to avoid freeze-thaw cycles. Some suppliers recommend brief centrifugation before opening the vial.
๐งStorage Requirements
Store lyophilized peptide at -20 degrees C, protected from light and moisture. Reconstituted solutions should be aliquoted into single-use volumes and stored at -20 degrees C or -80 degrees C. Avoid repeated freeze-thaw cycles. Working solutions should be prepared fresh for each experiment when possible.
Community Dosing Protocols
Compare these clinical doses with what 5+ community members report using.
Based on 5+ community reports
View community protocolsResearch Tools
Before You Begin
Review safety warnings and contraindications before starting any protocol.
Preclinical Research Status#
Tat-Beclin-1 has not been evaluated in human clinical trials. All dosing information below is derived from preclinical in vitro and in vivo research studies. No validated human dosing protocols exist. Tat-Beclin-1 is used exclusively as a research tool compound.
In Vitro Dosing#
Concentration Ranges#
Published in vitro studies have used Tat-Beclin-1 at various concentrations depending on the experimental system:
| Application | Concentration Range | Cell Type | Reference |
|---|---|---|---|
| Autophagy induction | 5-20 micromolar | Multiple cell lines | Shoji-Kawata et al. 2013 |
| HIV-1 inhibition | 0.5-5 micromolar | Macrophages | Shoji-Kawata et al. 2013 |
| Virus titer reduction | 5-20 micromolar | HeLa cells | Shoji-Kawata et al. 2013 |
| Autosis induction | Above 20-50 micromolar | HeLa cells | Liu et al. 2013 |
Critical Dose Considerations#
The dose-response relationship for Tat-Beclin-1 has a critical feature: at lower concentrations it induces beneficial autophagy, while at higher concentrations it triggers autosis (autophagy-dependent cell death). This creates a therapeutic window that must be carefully defined for each experimental system.
- Subtherapeutic: Below the threshold for measurable autophagy induction
- Therapeutic range: Sufficient autophagy induction for experimental endpoints
- Toxic range: Excessive autophagy leading to autosis
Control Peptides#
Tat-Scrambled peptide (containing the same amino acid composition in a scrambled sequence) is the standard negative control, confirming that observed effects are sequence-specific rather than due to non-specific cell penetration.
In Vivo Dosing#
Antiviral Studies#
In the foundational Nature 2013 study:
- Species: Mice (6-week-old C57BL/6 and GFP-LC3 transgenic)
- Dose: 15 mg/kg body weight
- Route: Intraperitoneal (IP) injection
- Frequency: Daily
- Start: 1 day post-infection
- Duration: 20 days
- Virus models: West Nile virus, chikungunya virus
- Outcome: Reduced mortality in virus-infected mice
- Form: Retro-inverso D-form preferred for in vivo stability
Anticancer Studies#
In the PNAS 2018 HER2 breast cancer study:
- Species: Nude mice bearing BT-474-VH2 xenografts
- Route: Intraperitoneal (IP) injection
- Frequency: Daily
- Start: When tumor volume reached 200 mm3
- Outcome: Tumor growth suppression comparable to lapatinib
- Comparator: Tat-Scrambled (negative control), lapatinib (positive control)
Species Translation Limitations#
Mouse dosing cannot be directly translated to human equivalent doses for Tat-Beclin-1 because:
- No human pharmacokinetic data exists
- The peptide's biodistribution and tissue penetration in humans are unknown
- Human protease profiles differ from mouse
- The therapeutic window between autophagy induction and autosis in human tissues is uncharacterized
Form Selection for Research#
| Research Setting | Recommended Form | Rationale |
|---|---|---|
| Cell culture (short exposure) | L-form (Tat-L11) | Adequate stability for hours-long experiments |
| Cell culture (prolonged) | D-form (Tat-D11) | Resists proteolytic degradation in culture media |
| In vivo mouse studies | D-form (Tat-D11) | Essential for in vivo stability |
| Structural studies | L-form (Tat-L11) | Natural chirality for protein interaction studies |
Fundamental Dosing Unknowns#
Critical gaps in Tat-Beclin-1 dosing knowledge include:
- Human pharmacokinetics: No ADME data in any primate species
- Bioavailability: Only IP injection studied in vivo; no oral, SC, or IV data
- CNS penetration: Limited data on blood-brain barrier crossing
- Tissue distribution: Incomplete characterization of tissue biodistribution
- Autosis threshold: Not defined in human cells or tissues
- Chronic toxicity: Only 20-day dosing studied; longer-term effects unknown
Related Reading#
Subscribe to see vendor options
Free access to verified vendor scores, pricing, and suppliers.
150+ peptide profiles ยท 30+ comparisons ยท 18 research tools
Protocol updates
Get notified when we update dosing protocols or publish related comparisons.
Frequently Asked Questions About Tat-Beclin-1
Explore Further
Medical Disclaimer
This website is for educational and informational purposes only. The information provided is not intended to diagnose, treat, cure, or prevent any disease. Always consult with a qualified healthcare professional before using any peptide or supplement.